Shibata Eiji, Rajakumar Augustine, Powers Robert W, Larkin Robert W, Gilmour Carol, Bodnar Lisa M, Crombleholme William R, Ness Roberta B, Roberts James M, Hubel Carl A
Magee-Womens Research Institute, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, Pennsylvania 15213, USA.
J Clin Endocrinol Metab. 2005 Aug;90(8):4895-903. doi: 10.1210/jc.2004-1955. Epub 2005 May 10.
An excess of the soluble receptor, fms-like tyrosine kinase 1 (sFlt-1) may contribute to maternal vascular dysfunction in women with preeclampsia by binding and thereby reducing concentrations of free vascular endothelial growth factor and placental growth factor (PlGF) in the circulation. The putative stimulus for increased sFlt-1 during preeclampsia, placental hypoxia due to poor perfusion, is common to both preeclampsia and idiopathic intrauterine growth restriction. However, the latter condition occurs without maternal vascular disease.
We asked whether, as with preeclampsia, sFlt-1 is increased and free PlGF is decreased in villous placenta and maternal serum of normotensive women with small-for-gestational-age (SGA) neonates.
This was a case-control study using banked samples. Groups of women with SGA neonates (birth weight centile < 10th) and women with preeclampsia were matched to separate sets of normal pregnancy controls based on gestational age at blood sampling (serum) or gestational age at delivery (placenta).
sFlt-1 levels were higher in preeclamptics than controls (serum, P < 0.0001; placental protein, P = 0.03; placental mRNA, P = 0.007) but not increased in SGA pregnancies. PlGF was lower in both preeclampsia (serum, P < 0.0001; placental protein, P = 0.05) and SGA (serum, P = 0.0008; placental protein, P = 0.03) compared with their controls. PlGF in preeclampsia and SGA groups did not differ.
These data are consistent with a role for sFlt-1 in the maternal manifestations of preeclampsia. In contrast to preeclampsia, sFlt-1 does not appear to contribute substantially to decreased circulating free PlGF in SGA pregnancies in the absence of a maternal syndrome.
可溶性受体——类fms酪氨酸激酶1(sFlt-1)过量,可能通过结合并降低循环中游离血管内皮生长因子和胎盘生长因子(PlGF)的浓度,导致子痫前期女性出现母体血管功能障碍。子痫前期期间sFlt-1升高的假定刺激因素——因灌注不良导致的胎盘缺氧,在子痫前期和特发性胎儿生长受限中都很常见。然而,后者在没有母体血管疾病的情况下发生。
我们探讨了与子痫前期一样,sFlt-1在小于胎龄(SGA)新生儿的血压正常的孕妇的绒毛胎盘和母体血清中是否升高,游离PlGF是否降低。
这是一项使用储存样本的病例对照研究。将SGA新生儿(出生体重百分位数<第10百分位数)的孕妇组和子痫前期孕妇组,根据采血时的孕周(血清)或分娩时的孕周(胎盘),与各自的正常妊娠对照组进行匹配。
子痫前期患者的sFlt-1水平高于对照组(血清,P<0.0001;胎盘蛋白,P = 0.03;胎盘mRNA,P = 0.007),但在SGA妊娠中未升高。与对照组相比,子痫前期(血清,P<0.0001;胎盘蛋白,P = 0.05)和SGA(血清,P = 0.0008;胎盘蛋白,P = 0.03)患者的PlGF均较低。子痫前期组和SGA组的PlGF无差异。
这些数据支持sFlt-1在子痫前期母体表现中的作用。与子痫前期不同,在没有母体综合征时,sFlt-1似乎对SGA妊娠中循环游离PlGF的降低没有实质性影响。